Antiarrhythmics Versus Implantable Defibrillators (AVID)
Note that you will be prompted to log in or register an account
Accession Number
HLB00160202a
Study Type
Clinical Trial
Collection Type
Open BioLINCC Study
See bottom of this webpage for request information
Study Period
1992-2002
NHLBI Division
DCVS
Dataset(s) Last Updated
January 3, 2018
Clinical Trial URLs
https://clinicaltrials.gov/ct2/show/NCT00000531
Primary Publication URLs
N/A
Consent
Commercial Use Data Restrictions No
Data Restrictions Based On Area Of Research No
Objectives
To evaluate if use of an implantable cardiac defibrillator (ICD) results in reduction in total mortality, when compared with conventional pharmacological therapy, in patients resuscitated from sudden cardiac death who are otherwise at very high risk of mortality from arrhythmic causes.
Background
Sudden cardiac death is believed to account for a substantial portion of deaths with evidence of cardiovascular disease. The majority of sudden cardiac deaths are thought to be due to ventricular fibrillation or tachycardia. Currently the most common approach to preventing sudden cardiac death has been using drugs that suppress ventricular ectopy. However, given the disappointing results of most pharmacologic approaches to preventing sudden death, many investigators have turned to non-pharmacologic approaches such as surgery (endocardial resection, stellate ganglionectomy) or the implantation of devices that recognize VT or VF and deliver a shock. The greatest interest has been generated by work on the implantable cardiac defibrillator.
Participants
The study was designed in two phases. The pilot phase enrolled 200 patients between June 194 and June 1994. Data collected during the pilot phase cofirmed the trial was feasible. An additional 1,000 patients was subsequently enrolled.
Design
At approximately 28 clinical sites, patients with ventricular tachycardia or ventricular fibrillation were screened. Patients meeting the criteria were randomized to treatment with an ICD or treatment with antiarrhythmic drug therapy. Patients were followed every 3 months for assessment of secondary endpoints, to record therapies delivered by the ICD and potential adverse effects of the ICD, and to assess compliance and potential adverse symptoms in patients treated with anti arrhythmic drugs.
Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.
Resources Available
Study Datasets OnlyStudy Documents
- Data Dictionary (PDF - 898.1 KB)
- Code Manual (PDF - 515.6 KB)
- Contents (PDF - 70.7 KB)
- Manual of Operations (PDF - 361.6 KB)
- Protocol (PDF - 163.9 KB)
- Forms
Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.